

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Brand, et al.
SERIAL NUMBER: 10/517,135 EXAMINER : Gyan Chandra
FILING DATE: February 17, 2006 ART UNIT : 1646
FOR: COMPOSITIONS AND METHODS FOR TREATING DIABETES

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (1 page), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of Cited References: C1-8; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24492-010 NATL. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

David E. Johnson, Reg. No. 41,874

Attorney(s) for Applicants

MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to


Customer No.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: July 27, 2007

Express Mail Label No.: EV 871031056 US
Date of Deposit: July 27, 2007



Attorney Docket No.: 24492-010 NATL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Brand, et al.
SERIAL NUMBER: 10/517,135 EXAMINER : Gyan Chandra
FILING DATE: February 17, 2006 ART UNIT : 1646
FOR: COMPOSITIONS AND METHODS FOR TREATING DIABETES

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are enclosed.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed due. By the waiver of 37 CFR 1.98(a)(2)(ii) copies of the U.S. Patents A1-A2 are not submitted. However, please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 24492-010 NATL.

Respectfully submitted,

David E. Johnson, Reg. No. 41,874

Attorney(s) for Applicants

MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer No.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: July 27, 2007

Express Mail Label No.: EV 871031056 US
Date of Deposit: July 27, 2007



Page 1 of 1
Attorney Docket No.: 24492-010 NATL

Please type a plus sign (+) in this box +

PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number		10/517,135	
				Filing Date of U.S. Nat'l Appl.		February 17, 2006	
				First Named Inventor		Brand	
				Group Art Unit		1646	
				Examiner Name		Gyan Chandra	
				Attorney Docket Number		24492-010 NATL	
U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A1	5,624,895	04/29/97	Sobel	514	8	
	*A2	5,885,956	03/23/99	Nardi, et al.	514	2	
FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)		Date of Publication	Translation Yes No	
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C1	Carpenter, et al., "The Epidermal Growth Factor Family", <i>Eds. Sporn and Roberts</i> , Chapter 4:69-171 (1990)					
	C2	Fridkis-Hareli, et al., "Novel Synthetic Amino Acid Copolymers that Inhibit Autoantigen-Specific T Cell Responses and Suppress Experimental Autoimmune Encephalomyelitis", <i>J. Clin. Invest.</i> , 109(12):1635-1643 (2002)					
	C3	Lin, et al., "A71378: a CCK Agonist with High Potency and Selectivity for CCK-A Receptors", <i>Am. J. Physiol.</i> , 258(4 Pt 1):G648-G651 (1990)					
	C4	Rooman, et al., "Gastrin Stimulates β -Cell Neogenesis and Increases Islet Mass From Transdifferentiated but not from Normal Exocrine Pancreas Tissue", <i>Diabetes</i> , 51(3):686-690 (2002)					
	C5	Sasaki, et al., "Dietary Docosahexaenoic Acid Can Alter the Surface Expression of CD4 and CD8 on T Cells in Peripheral Blood", <i>J. Agric. Food Chem.</i> , 48(4):1047-1049 (2000).					
	C6	Selinfreund, et al., "Antisense Inhibition of Glial S100 β Production Results in Alterations in Cell Morphology, Cytoskeletal Organization, and Cell Proliferation", <i>J. Cell Biol.</i> , 111:2021-2028 (1990)					
	C7	Vergelli, et al., "Immunosuppressive Activity of 13-cis-Retinoic Acid in Rats: Aspects of Pharmacokinetics and Pharmacodynamics", <i>Immunopharmacology</i> , 37:191-197 (1997)					
	C8	Winer, et al., "Autoimmune Islet Destruction in Spontaneous Type 1 Diabetes is not β -Cell Exclusive", <i>Nature Medicine</i> , 9(2):198-205 (2003)					

* By the waiver of 37 CFR 1.98(a)(2)(ii) copies of the U.S. Patents A1-A2 are not submitted.

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.